Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash & Equivalents (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Cash & Equivalents for 5 consecutive years, with $165.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 9.8% year-over-year to $165.6 million, compared with a TTM value of $165.6 million through Dec 2025, down 9.8%, and an annual FY2025 reading of $165.6 million, down 9.8% over the prior year.
  • Cash & Equivalents was $165.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $352.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $352.1 million in Q3 2025 and bottomed at $63.3 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $168.6 million, with a median of $166.8 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents plummeted 76.02% in 2022, then skyrocketed 93.45% in 2025.
  • Year by year, Cash & Equivalents stood at $122.5 million in 2021, then increased by 0.2% to $122.7 million in 2022, then dropped by 12.03% to $108.0 million in 2023, then skyrocketed by 70.05% to $183.6 million in 2024, then decreased by 9.8% to $165.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for KNSA at $165.6 million in Q4 2025, $352.1 million in Q3 2025, and $192.0 million in Q2 2025.